AMRI (NASDAQ: AMRI) announced today that Richard A. Saffee has been promoted to the newly created role of Vice President and General Manager of Large Scale Manufacturing, effective immediately. He will continue to report to Steven R. Hagen, Ph.D., Senior Vice President of Pharmaceutical Development and Manufacturing.
Mr. Saffee will assume oversight for large scale manufacturing in Aurangabad, India in addition to his current responsibilities for leadership of AMRI’s large scale manufacturing and GMP business in the United States in the Capital Region of New York. Additionally, Mr. Saffee will work with AMRI’s Holywell, UK site to assist them in their large scale manufacturing business. Mr. Saffee will be positioned to drive synergies between the locations that will improve quality, efficiency and delivery of world class API’s.
“We are pleased to announce this promotion of Mr. Saffee,” said Dr. Hagen. “Mr. Saffee joined AMRI in 2009 with more than 23 years of industrial and leadership experience in the chemical manufacturing of bulk Active Pharmaceutical Ingredients (API) for both human and animal health. Since joining AMRI, Rick’s leadership has been instrumental in many successes achieved at the Rensselaer large scale manufacturing location. We look forward to his leadership in our continued efforts to achieve closer integration among all of our manufacturing facilities.”
Backed by an excellent compliance history and track record, AMRI’s worldwide manufacturing facilities are equipped for Phase I through commercial API manufacturing. As a part of AMRI’s SMARTSOURCING™ initiative, this closer integration of facilities under Mr. Saffee provides an added advantage as customers move their compounds from early development to high potency and large scale manufacturing. These global sites in the United States, Europe and Asia also provide tailored solutions for the biotech and pharma industry, and enable the efficient, cost-effective transfer of products and projects. AMRI also provides raw materials and starting materials for cGMP manufacturing of API.
Before coming to AMRI, Mr. Saffee led manufacturing activities for multiple U.S.-based operations for Pfizer Global Manufacturing. and Pfizer Global Human Health. Prior to the acquisition of Parke-Davis by Pfizer, Mr. Saffee held roles of increasing responsibility at Parke-Davis including Director of Chemical Manufacturing and Area Production Manager. He has extensive knowledge in the areas of chemical manufacturing, technology transfer, regulatory compliance and quality standards, purchasing and materials management and managing global relationships. He is also trained in Lean Six Sigma techniques.
Mr. Saffee earned a Master’s degree in Business Administration from Grand Valley State University in Allendale, Michigan and a Bachelor’s of Science degree in Chemical Engineering from the University of Michigan in Ann Arbor, Michigan.
Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).
About AMRI Rensselaer
AMRI’s 23-acre Rensselaer site is located in New York State and provides contract cGMP manufacturing of bulk active pharmaceuticals and advanced intermediates for clinical phase scale-up requirements up to and including full scale commercial manufacturing. The facility, which hosts over 35 customer audits each year, maintains an excellent U.S. Federal Drug Administration (FDA) quality inspection record and is fully licensed by the U.S. Drug Enforcement Administration (DEA) to produce Schedule I, II, III, IV and V controlled substances. The site, which received its SafeBridge Potent Compound Safety Certification in 2010, has a state-of-art high-potency compound production facility that can handle quantities from grams to 120 kgs. Combining a scientifically strong staff with our highly experienced workforce allows the Rensselaer site to deliver its best to our customers. Currently, 26 Commercial Products are routinely manufactured from 25 kg individual batches to 7 metric ton annual campaigns.
About AMRI India Operations
In India, AMRI offers cost-competitive chemical synthesis and kilo lab work, as well as a reliable, large-scale manufacturing source for starting materials and intermediates. AMRI established its presence in India in 2007. Since that time, capabilities have been built in the areas of chemical synthesis and manufacturing, keeping AMRI’s core values of Safety, Quality and Customer Satisfaction and Service at the forefront of the Company’s business objectives. Today, AMRI in India has significant capabilities and capacity across the Custom Research and Manufacturing Services (CRAMS) space. AMRI’s Global Project Management Team has access to the extensive experience and capabilities of all of the Company’s global locations, and can tap into the collective problem solving and brainpower of industry experienced managers as needed. Numerous projects are in progress or have been completed using this integrated model, and AMRI’s operations in Hyderabad and Aurangabad, India, are especially well-suited to be a centerpiece of a global project team.
About AMRI UK
AMRI UK provides development and manufacturing services, including pre-clinical and Phase I – III product development, as well as commercial manufacturing for approved products. The 14-acre site is located about 60 miles outside of Manchester, England and contains Kilo lab, pilot plant and large-scale manufacturing capabilities. In 2012, the site received a Good Manufacturing Practice (GMP) certificate from the Medicines and Healthcare Regulatory Agency (MHRA) of the UK government for AMRI’s manufacturing facility in Holywell, Wales, UK, underscoring the quality of the facility and its growth potential.
Investors – Michael Nolan, AMRI Chief Financial Officer, 518-512-2261
Media – Gina Monari, AMRI Communications, 518-512-2512